Navigation Links
Treatment with A1-PI slows the progression of emphysema in Alpha-1 antitrypsin deficiency
Date:5/21/2013

ATS 2013, PHILADELPHIA─Treatment with an Alpha-1 proteinase inhibitor (A1-PI), a naturally occurring protein that protects lung tissue from breakdown and protects the lung's elasticity, is effective in slowing the progression of emphysema in patients with Alpha-1 antitrypsin deficiency (AATD), a life-threatening genetic disorder, according to a new study presented at the 2013 American Thoracic Society International Conference.

The study showed the efficacy of A1-PIin preventing the loss of lung tissue as measured by computed tomography (CT) scan lung density at full inspiration (TLC), which is a more sensitive measure of disease progression than conventional parameters.This is the first prospective study to demonstrate the efficacy and safety of augmentation therapy in a randomized, placebo-controlled trial using this parameter.

"Our experience of the last quarter century has been that augmentation therapy is associated with better preserved lung function and reduced mortality, " said lead author Kenneth R. Chapman, M.D., director of the Asthma and Airway Centre of the University Health Network, in Toronto. "This randomized, placebo-controlled trial using a sensitive measure of lung density adds the most rigorous evidence to date that augmentation therapy slows the progression of emphysema in patients with Alpha-1 antitrypsin deficiency. The effect of A1-PI seen in this trial was both clinically and statistically significant, finally confirming its benefit in preventing the loss of lung tissue in patients with this potentially debilitating disease."

Chapman added that preliminary data from an extension trial suggest that early treatment with A1-PIshows persistent efficacy in patients with AATD and emphysema. In both the A1-PI and placebo groups who elected to continue treatment withA1-PI 60 mg/kg weekly, the benefit in CT scan lung density decline continued.

AATD is a hereditary condition that can severely affect a patient's lung function. The condition is marked by a low level or absence of A1-PI, a natural protein that protects the lung from breakdown by inhibiting neutrophil elastase, and protects lung elasticity. AATD can lead to emphysema at a young age (<45 years of age), especially among smokers, and progressive loss of lung function that can significantly impact everyday life and life expectancy.

There is no cure for AATD, but there are treatments for the symptoms of the disease, including bronchodilators and inhaled steroids, which help open the airways. Augmentation therapy, which is administered intravenously, has been shown to slow or halt the destruction of lung tissue in AATD.

The current trial, the largest clinical trial of this treatment to date, was a randomized, placebo-controlled, double-blind, multinational, multicenter phase III/IV study comparing the efficacy and safety ofA1-PIwith placebo in 180 subjects with emphysema due to AATD. Patients received A1-PIintravenously 60 mg/kg weekly or matching placebo over two years. The effect ofA1-PI on the progression of emphysema, the primary endpoint of the study, was assessed by the decline of lung density, measured by CT scan. Key secondary endpoints included changes in exercise capacity, symptoms score and rate of pulmonary exacerbations over two years.

There was no difference between groups in baseline characteristics: mean age 53.1 +/- 7.4 year; forced expiratory volume in 1 second (FEV1) 48.9 +/- 11.7%. According to study findings, the annual rate of lung density loss was significantly less in A1-PI-treated patients (-1.45 +/- 0.24 units vs. -2.19 +/-0.25 units; p = 0.017, one sided). Secondary outcome variables and the few adverse reactions reported were not significantly different between groups.

"The augmentation treatment used in the current study is not known to have a role in emphysema caused by tobacco smoking unrelated to alpha-1 antitrypsin deficiency, and our findings apply to a particular type of genetically-related emphysema," said Dr. Chapman. "Furthermore, our findings show preservation, but not restoration, of lung tissue. That is, the treatment slows the damage for people with alpha-1 antitrypsin deficiency but does not repair the damage."

"Although augmentation therapy has been well accepted in the United States, it has been slow to gain acceptance in other countries where augmentation therapy may be unavailable and/or unfunded. Our positive findings may encourage more widespread use of this treatment," said Dr. Chapman.

"With 2013 marking the 50th anniversary of the discovery of Alpha-1 antitrypsin deficiency, we are excited to now have confirmation of the clinical efficacy of this therapy in reducing the loss of lung tissue in Alpha-1 patients who have emphysema, " said Gerry McElvaney, professor of medicine at Royal College of Surgeons of Ireland, and principal investigator of the trial.


'/>"/>

Contact: Nathaniel Dunford
ndunford@thoracic.org
American Thoracic Society
Source:Eurekalert

Related medicine news :

1. Child maltreatment increases risk of adult obesity
2. New Natural Vitiligo Treatment System That Helps People Treat Vitiligo Permanently Revealed by Daily Gossip Magazine
3. Study supports aggressive treatment for posterior fossa hematoma in newborns
4. Discovery of a novel medicine for the treatment of chronic wounds
5. Delaware Dermatologist Now Offers Clear + Brilliant Gentle Laser Skin Rejuvenation Treatments
6. hCGTreatments / Diet Doc hCG Diets & Weight Loss Offers improved hCG Diets With More Beneficial Nutritional Content, Possibly Offering Relief for Painful Symptoms of IBS
7. hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces New Improved hCG Diet Helping Patient’s Control Eating Impulses
8. Body Firming – The Hottest Treatments Available
9. hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer
10. hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announce the Best Weight Loss Through New Whole Foods, Healthy Snacks and Prescription Strength hCG Treatments
11. Spice Addiction Treatment and Synthetic Marijuana Drug Rehab Announced by Recovery Associates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... , ... December 07, 2016 , ... ... 2016 BOC Business Brilliance Awards under the Best New Product Launch category. Gensuite’s ... achieved through user experience. , BOC Global Events & Training Group is a ...
(Date:12/7/2016)... ... ... “The Road To Restoration”: an informative and enlightening book for those who ... of hands. “The Road To Restoration” is the creation of published author, Thomas Fitzhugh ... ring that you could reach out for, and grab, on the old carousels. ...
(Date:12/7/2016)... ... 2016 , ... “Fred Rides a Train” allows readers to tag along on ... Rides a Train” is the creation of published author, Janet Morrison, who has been ... Michigan. The "Fred, the Dog" series is her first attempt at writing for children. ...
(Date:12/7/2016)... ... December 07, 2016 , ... Dr. Greg ... the International Probiotic Association’s Washington DC workshop on November 2nd. The conference was ... dialog regarding probiotic dietary supplement regulations. , Dr. Leyer spoke about two ...
(Date:12/6/2016)... ... 06, 2016 , ... People with Parkinson’s disease and cognitive ... type of MRI, according to a study appearing online in the journal Radiology. ... characterized by tremors or trembling and stiffness in the limbs, impaired balance and ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)...  Alopexx Oncology, LLC announced data from a Phase ... (immunocytokine) composed of interleukin-2 and a CD20-targeting monoclonal antibody. ... cells as Rituxan and maintains the activities of both ... in tumor targeting, engagement of the immune system, and ... the study (abstract #95954) were presented at the 58 ...
(Date:12/6/2016)... -- Radioisotopes are radioactive isotopes having an unstable balance ... nuclear research reactor or by using cyclotron. These isotopes ... gamma when changed to a stable nature. The gamma ... in medical diagnostics. In this field, the radiation is ... functioning. Radiotherapy is also used to treat some life-threatening ...
(Date:12/6/2016)... Homozygous Familial Hypercholesterolemia (HoFH) - ... Global Markets Direct,s latest Pharmaceutical and Healthcare ... – Pipeline Review, H2 2016, provides an ... (Metabolic Disorders) pipeline landscape. Homozygous familial ... caused due to mutation from both parents. ...
Breaking Medicine Technology: